Yelena Piazza
Overview
Explore the profile of Yelena Piazza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
5
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fakhre F, Piazza Y, Neychev V
Cureus
. 2025 Feb;
17(1):e77038.
PMID: 39917150
Soft tissue masses in the lower extremities present significant diagnostic challenges due to the broad spectrum of potential etiologies, ranging from benign to malignant tumors. A 69-year-old woman presented to...
2.
Clabby K, Piazza Y, Neychev V
Cureus
. 2025 Jan;
16(12):e75183.
PMID: 39759670
Sarcoidosis is a multisystem disease process with a bimodal distribution typically affecting African American women and those of Scandinavian descent characterized by noncaseating granulomatous disease. We present a case of...
3.
Kubiszewski K, Chapman R, Piazza Y, Patel D, Neychev V
Cureus
. 2024 Jan;
15(12):e50799.
PMID: 38239558
Patients who present with nausea, vomiting, constipation, and abdominal pain typically undergo workups for small bowel obstruction (SBO). SBO is commonly caused by mechanical obstruction due to adhesions, inflammatory conditions,...
4.
Kubiszewski K, Hunsaker P, Piazza Y, Patel D, Neychev V
Cureus
. 2023 Oct;
15(9):e45706.
PMID: 37868470
Small-cell neuroendocrine carcinoma, often classified as small-cell lung carcinoma (SCLC) type, is an aggressive neuroendocrine tumor with early metastatic potential that can lead to unexpected patient presentations. We report the...
5.
Thadi A, Morano W, Khalili M, Babcock B, Shaikh M, Foster D, et al.
Anticancer Res
. 2021 Jan;
41(1):27-42.
PMID: 33419797
Background/aim: We have tested whether the anticancer peptide, PNC-27, that kills cancer cells but not normal cells by binding to cancer cell membrane HDM-2 forming pores, kills CD44+ colon cancer...